Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Eiger Biopharma (EIGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 254,088
  • Shares Outstanding, K 19,095
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,450 K
  • 36-Month Beta 1.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.83
  • Number of Estimates 4
  • High Estimate -0.76
  • Low Estimate -0.90
  • Prior Year -1.11
  • Growth Rate Est. (year over year) +25.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.50 +6.24%
on 01/16/19
14.84 -10.51%
on 02/06/19
+0.58 (+4.57%)
since 01/15/19
3-Month
8.40 +58.10%
on 11/20/18
14.84 -10.51%
on 02/06/19
+4.04 (+43.72%)
since 11/15/18
52-Week
8.20 +61.95%
on 05/03/18
18.00 -26.22%
on 05/18/18
+4.68 (+54.42%)
since 02/15/18

Most Recent Stories

More News
Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, announced today that the European Patent Office and...

EIGR : 13.28 (-0.23%)
Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced an oral presentation has been granted for results...

EIGR : 13.28 (-0.23%)
Report: Exploring Fundamental Drivers Behind Cronos Group, Henry Schein, Argo Group International, Eiger BioPharmaceuticals, China Automotive, and Moleculin Biotech -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cronos Group Inc. (NASDAQ:CRON),...

CRON : 21.29 (+2.26%)
HSIC : 62.39 (+0.03%)
ARGO : 68.45 (+1.69%)
AGII : 58.85 (+5.37%)
EIGR : 13.28 (-0.23%)
CAAS : 3.18 (-9.66%)
MBRX : 1.47 (unch)
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration...

EIGR : 13.28 (-0.23%)
Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the European Medicines Agency (EMA)...

EIGR : 13.28 (-0.23%)
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration...

EIGR : 13.28 (-0.23%)
Eiger BioPharmaceuticals Reports on 2018 R&D Day

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced recent accomplishments reported at...

EIGR : 13.28 (-0.23%)
Eiger BioPharmaceuticals to Host R&D Day in New York City

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced it will host an R&D Day on December...

EIGR : 13.28 (-0.23%)
Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced the appointment of Sri Ryali as the...

AMGN : 188.34 (+0.89%)
EIGR : 13.28 (-0.23%)
Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration...

EIGR : 13.28 (-0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade EIGR with:

Business Summary

Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California.

See More

Key Turning Points

2nd Resistance Point 13.61
1st Resistance Point 13.45
Last Price 13.28
1st Support Level 13.09
2nd Support Level 12.89

See More

52-Week High 18.00
Fibonacci 61.8% 14.26
Last Price 13.28
Fibonacci 50% 13.10
Fibonacci 38.2% 11.94
52-Week Low 8.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar